Idogen is a research company. The company's business focus is on developing vaccines for the treatment of diseases that adversely affect the immune system. The vaccines are intended to be used in the cases where autoimmune diseases have occurred and after organ rejection, particularly in the cases where antibodies have been formed against the ingestion of the regular medication of the patient. The company was founded in 2008 and is based in Lund.

Quotes for Idogen AB

Right Now

+/-
0.47
%
51,09%
Latest
1.39
High
1.39
Low
1.05
Volume
1 026 483
Turnover (SEK)
1 213 053
Value (MSEK)
67,4

Board

CEO

  • Lars Hedbys

Chairman Of The Board

  • Agneta Edberg

Board

  • Christina Herder
  • Karin Hoogendoorn
  • Leif G Salford

Videos

Largest Owners

Name Capital % Votes % Date
Danica Pension 12,75 12,75 2019-03-31
Avanza Pension 6,17 6,17 2019-03-31
Leif G Salford 3,37 3,37 2018-12-05
Anders Böös 2,36 2,36 2019-03-31
Mikael Lönn 1,96 1,96 2019-03-31
Johan Thorell 1,59 1,59 2019-03-31
Ventac Holding (Cyprus) Ltd 1,57 1,57 2019-03-31
HCN Group AB 1,56 1,56 2019-03-31
Nils Berntsson 1,55 1,55 2019-03-31
Swedbank Försäkring 1,55 1,55 2019-03-31
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Inquiry Financial

Upcoming reports

  • 2019-06-25 Årsstämma 2018

  • 2019-08-20 Delårsrapport 2019-Q2

  • 2019-10-22 Delårsrapport 2019-Q3

  • 2020-02-11 Bokslutskommuniké 2019